@article{Su2022920,

title = {AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma},

author = {Grace L. Su and Osama Altayar and Robert O'Shea and Raj Shah and Bassam Estfan and Candice Wenzell and Shahnaz Sultan and Yngve Falck-Ytter},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85125309277&doi=10.1053%2fj.gastro.2021.12.276&partnerID=40&md5=a1859600a1f8fbfe3313b5ac84e921fb},

doi = {10.1053/j.gastro.2021.12.276},

issn = {00165085},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {Gastroenterology},

volume = {162},

number = {3},

pages = {920 – 934},

publisher = {W.B. Saunders},

abstract = {Background & Aims: Hepatocellular carcinoma (HCC), the most common primary liver cancer, remains a deadly cancer, with an incidence that has tripled in the United States since 1980. In recent years, new systemic therapies for HCC have been approved and a critical assessment of the existing data is necessary to balance benefits and harms and inform the development of evidence-based guidelines. Methods: The American Gastroenterological Association formed a multidisciplinary group consisting of a Technical Review Panel and a Guideline Panel. The Technical Review Panel prioritized clinical questions and outcomes according to their importance for clinicians and patients and conducted an evidence review of systemic therapies in patients with advanced-stage HCC. The Grading of Recommendations Assessment, Development and Evaluation framework was used to assess evidence. The Guideline Panel reviewed the evidence and used the Evidence-to-Decision Framework to develop recommendations. Results: The Panel reviewed the evidence, summarized in the Technical Review, for the following medications approved by the US Food and Drug Administration for HCC: first-line therapies: bevacizumab+atezolizumab, sorafenib, and lenvatinib; second-line therapies: cabozantinib, pembrolizumab, ramucirumab, and regorafenib; and other agents: bevacizumab, nivolumab, and nivolumab+ipilimumab. Conclusions: The Panel agreed on 11 recommendations focused on systemic therapy for HCC in patients who are not eligible for locoregional therapy or resection, those with metastatic disease and preserved liver function, those with poor liver function, and those on systemic therapy as adjuvant therapy. © 2022},

note = {Cited by: 7; All Open Access, Bronze Open Access},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Reig2022681,

title = {BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update},

author = {Maria Reig and Alejandro Forner and Jordi Rimola and Joana Ferrer-Fàbrega and Marta Burrel and Ángeles Garcia-Criado and Robin K. Kelley and Peter R. Galle and Vincenzo Mazzaferro and Riad Salem and Bruno Sangro and Amit G. Singal and Arndt Vogel and Josep Fuster and Carmen Ayuso and Jordi Bruix},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123587056&doi=10.1016%2fj.jhep.2021.11.018&partnerID=40&md5=36b700ec2237537cabf51cf558f1201c},

doi = {10.1016/j.jhep.2021.11.018},

issn = {01688278},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {Journal of Hepatology},

volume = {76},

number = {3},

pages = {681 – 693},

publisher = {Elsevier B.V.},

abstract = {There have been major advances in the armamentarium for hepatocellular carcinoma (HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and treatment strategy published in 2018. Whilst there have been advances in all areas, we will focus on those that have led to a change in strategy and we will discuss why, despite being encouraging, data for select interventions are still too immature for them to be incorporated into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that are required to make clinical decisions for individual patients, considering all of the parameters that must be considered to deliver personalised clinical management. © 2021 European Association for the Study of the Liver},

note = {Cited by: 118; All Open Access, Bronze Open Access},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Sun2022315,

title = {Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition)},

author = {Juxian Sun and Rongping Guo and Xinyu Bi and Mengchao Wu and Zhaoyou Tang and Wan Yee Lau and Shusen Zheng and Xuehao Wang and Jinming Yu and Xiaoping Chen and Jia Fan and Jiahong Dong and Yongjun Chen and Yunfu Cui and Chaoliu Dai and Chihua Fang and Shuang Feng and Zhili Ji and Weidong Jia and Ningyang Jia and Gong Li and Jing Li and Qiu Li and Jiangtao Li and Tingbo Liang and Lianxin Liu and Shichun Lu and Yi Lv and Yilei Mao and Yan Meng and Zhiqiang Meng and Feng Shen and Jie Shi and Huichuan Sun and Kaishan Tao and Gaojun Teng and Xuying Wan and Tianfu Wen and Liqun Wu and Jinglin Xia and Mingang Ying and Jian Zhai and Leida Zhang and Xuewen Zhang and Zhiwei Zhang and Haiping Zhao and Donghai Zheng and Xuting Zhi and Jie Zhou and Cuncai Zhou and Jian Zhou and Zhaochong Zeng and Kangshun Zhu and Minshan Chen and Jianqiang Cai and Shuqun Cheng},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85134527843&doi=10.1159%2f000523997&partnerID=40&md5=357f3f94ca73ee3dda1e4f3b0fbfb828},

doi = {10.1159/000523997},

issn = {22351795},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {Liver Cancer},

volume = {11},

number = {4},

pages = {315 – 328},

publisher = {S. Karger AG},

abstract = {Portal vein tumor thrombus (PVTT) is very common and it plays a major role in the prognosis and clinical staging of hepatocellular carcinoma (HCC). We have published the first version of the guideline in 2016 and revised in 2018. Over the past several years, many new evidences for the treatment of PVTT become available, especially for the advent of new targeted drugs and immune checkpoint inhibitors which have further improved the prognosis of PVTT. So, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association revised the 2018 version of the guideline to adapt to the development of PVTT treatment. Future treatment strategies for HCC with PVTT in China would depend on new evidences from more future clinical trials. © 2022 The Author(s).},

note = {Cited by: 0; All Open Access, Gold Open Access, Green Open Access},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Park2022583,

title = {2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma},

author = {Joong-Won Park},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85142044076&doi=10.3350%2fcmh.2022.0294&partnerID=40&md5=b5838b9c54cd59840bce79bac3c51b7c},

doi = {10.3350/cmh.2022.0294},

issn = {22872728},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {Clinical and Molecular Hepatology},

volume = {28},

number = {4},

pages = {583 – 705},

publisher = {Korean Association for the Study of the Liver},

abstract = {Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth most common cancer among men in South Korea, where the prevalence of chronic hepatitis B infection is high in middle and old age. The current practice guidelines will provide useful and sensible advice for the clinical management of patients with HCC. A total of 49 experts in the fields of hepatology, oncology, surgery, radiology, and radiation oncology from the Korean Liver Cancer Association-National Cancer Center Korea Practice Guideline Revision Committee revised the 2018 Korean guidelines and developed new recommendations that integrate the most up-to-date research findings and expert opinions. These guidelines provide useful information and direction for all clinicians, trainees, and researchers in the diagnosis and treatment of HCC. © 2022 by Korean Association for the Study of the Liver.},

note = {Cited by: 0; All Open Access, Gold Open Access, Green Open Access},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Vogel2021801,

title = {Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines},

author = {A. Vogel and E. Martinelli and A. Cervantes and I. Chau and B. Daniele and J. M. Llovet and T. Meyer and J. -C. Nault and U. Neumann and J. Ricke and B. Sangro and P. Schirmacher and C. Verslype and C. J. Zech and D. Arnold},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85104668795&doi=10.1016%2fj.annonc.2021.02.014&partnerID=40&md5=e7c9623620b0597e51ad4ccbb55fcfaf},

doi = {10.1016/j.annonc.2021.02.014},

issn = {09237534},

year  = {2021},

date = {2021-01-01},

urldate = {2021-01-01},

journal = {Annals of Oncology},

volume = {32},

number = {6},

pages = {801 – 805},

publisher = {Elsevier Ltd},

note = {Cited by: 70; All Open Access, Bronze Open Access},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Kudo2021181,

title = {Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update},

author = {Masatoshi Kudo and Yusuke Kawamura and Kiyoshi Hasegawa and Ryosuke Tateishi and Kazuya Kariyama and Shuichiro Shiina and Hidenori Toyoda and Yasuharu Imai and Atsushi Hiraoka and Masafumi Ikeda and Namiki Izumi and Michihisa Moriguchi and Sadahisa Ogasawara and Yasunori Minami and Kazuomi Ueshima and Takamichi Murakami and Shiro Miyayama and Osamu Nakashima and Hirohisa Yano and Michiie Sakamoto and Etsuro Hatano and Mitsuo Shimada and Norihiro Kokudo and Satoshi Mochida and Tetsuo Takehara},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85105634250&doi=10.1159%2f000514174&partnerID=40&md5=8f759fcb356b1e2690a392ba93be7b24},

doi = {10.1159/000514174},

issn = {22351795},

year  = {2021},

date = {2021-01-01},

urldate = {2021-01-01},

journal = {Liver Cancer},

volume = {10},

number = {3},

pages = {181 – 223},

publisher = {S. Karger AG},

abstract = {The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed by the Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma along with consensus opinion among a Japan Society of Hepatology (JSH) expert panel on hepatocellular carcinoma (HCC). Since the JSH Clinical Practice Guidelines are based on original articles with extremely high levels of evidence, expert opinions on HCC management in clinical practice or consensus on newly developed treatments are not included. However, the practice manual incorporates the literature based on clinical data, expert opinion, and real-world clinical practice currently conducted in Japan to facilitate its use by clinicians. Alongside each revision of the JSH Guidelines, we issued an update to the manual, with the first edition of the manual published in 2007, the second edition in 2010, the third edition in 2015, and the fourth edition in 2020, which includes the 2017 edition of the JSH Guideline. This article is an excerpt from the fourth edition of the HCC Clinical Practice Manual focusing on pathology, diagnosis, and treatment of HCC. It is designed as a practical manual different from the latest version of the JSH Clinical Practice Guidelines. This practice manual was written by an expert panel from the JSH, with emphasis on the consensus statements and recommendations for the management of HCC proposed by the JSH expert panel. In this article, we included newly developed clinical practices that are relatively common among Japanese experts in this field, although all of their statements are not associated with a high level of evidence, but these practices are likely to be incorporated into guidelines in the future. To write this article, coauthors from different institutions drafted the content and then critically reviewed each other's work. The revised content was then critically reviewed by the Board of Directors and the Planning and Public Relations Committee of JSH before publication to confirm the consensus statements and recommendations. The consensus statements and recommendations presented in this report represent measures actually being conducted at the highest-level HCC treatment centers in Japan. We hope this article provides insight into the actual situation of HCC practice in Japan, thereby affecting the global practice pattern in the management of HCC. © 2021 The Author(s). Published by S. Karger AG, Basel.},

note = {Cited by: 61; All Open Access, Gold Open Access, Green Open Access},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Zhou2020682,

title = {Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)},

author = {Jian Zhou and Huichuan Sun and Zheng Wang and Wenming Cong and Jianhua Wang and Mengsu Zeng and Weiping Zhou and Ping Bie and Lianxin Liu and Tianfu Wen and Guohong Han and Maoqiang Wang and Ruibao Liu and Ligong Lu and Zhengang Ren and Minshan Chen and Zhaochong Zeng and Ping Liang and Changhong Liang and Min Chen and Fuhua Yan and Wenping Wang and Yuan Ji and Jingping Yun and Dingfang Cai and Yongjun Chen and Wenwu Cheng and Shuqun Cheng and Chaoliu Dai and Wenzhi Guo and Baojin Hua and Xiaowu Huang and Weidong Jia and Yaming Li and Yexiong Li and Jun Liang and Tianshu Liu and Guoyue Lv and Yilei Mao and Tao Peng and Weixin Ren and Hongcheng Shi and Guoming Shi and Kaishan Tao and Wentao Wang and Xiaoying Wang and Zhiming Wang and Bangde Xiang and Baocai Xing and Jianming Xu and Jiamei Yang and Jianyong Yang and Yefa Yang and Yunke Yang and Shenglong Ye and Zhengyu Yin and Bixiang Zhang and Boheng Zhang and Leida Zhang and Shuijun Zhang and Ti Zhang and Yongfu Zhao and Honggang Zheng and Jiye Zhu and Kangshun Zhu and Rong Liu and Yinghong Shi and Yongsheng Xiao and Zhi Dai and Gaojun Teng and Jianqiang Cai and Weilin Wang and Xiujun Cai and Qiang Li and Feng Shen and Shukui Qin and Jiahong Dong and Jia Fan},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85097250039&doi=10.1159%2f000509424&partnerID=40&md5=22afea93bbf621b3079a7c5a8eed4925},

doi = {10.1159/000509424},

issn = {22351795},

year  = {2020},

date = {2020-01-01},

urldate = {2020-01-01},

journal = {Liver Cancer},

volume = {9},

number = {6},

pages = {682 – 720},

publisher = {S. Karger AG},

abstract = {Background: Primary liver cancer, around 90% are hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chinese people. Summary: Since the publication of Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2017 Edition) in 2018, additional high-quality evidence has emerged with relevance to the diagnosis, staging, and treatment of liver cancer in and outside China that requires the guidelines to be updated. The new edition (2019 Edition) was written by more than 70 experts in the field of liver cancer in China. They reflect the real-world situation in China regarding diagnosing and treating liver cancer in recent years. Key Messages: Most importantly, the new guidelines were endorsed and promulgated by the Bureau of Medical Administration of the National Health Commission of the People's Republic of China in December 2019. © 2020 S. Karger AG. All rights reserved.},

note = {Cited by: 131; All Open Access, Gold Open Access, Green Open Access},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Galle2018182,

title = {EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma},

author = {Peter R. Galle and Alejandro Forner and Josep M. Llovet and Vincenzo Mazzaferro and Fabio Piscaglia and Jean-Luc Raoul and Peter Schirmacher and Valérie Vilgrain},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85045123425&doi=10.1016%2fj.jhep.2018.03.019&partnerID=40&md5=c3cb9195eb9348189035bfe72636fff4},

doi = {10.1016/j.jhep.2018.03.019},

issn = {01688278},

year  = {2018},

date = {2018-01-01},

urldate = {2018-01-01},

journal = {Journal of Hepatology},

volume = {69},

number = {1},

pages = {182 – 236},

publisher = {Elsevier B.V.},

note = {Cited by: 3579; All Open Access, Hybrid Gold Open Access},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Marrero2018723,

title = {Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases},

author = {Jorge A. Marrero and Laura M. Kulik and Claude B. Sirlin and Andrew X. Zhu and Richard S. Finn and Michael M. Abecassis and Lewis R. Roberts and Julie K. Heimbach},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85051414295&doi=10.1002%2fhep.29913&partnerID=40&md5=32983adff5ff37b7f345efa648840e76},

doi = {10.1002/hep.29913},

issn = {02709139},

year  = {2018},

date = {2018-01-01},

urldate = {2018-01-01},

journal = {Hepatology},

volume = {68},

number = {2},

pages = {723 – 750},

publisher = {John Wiley and Sons Inc.},

note = {Cited by: 1758; All Open Access, Bronze Open Access},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Vogel2018iv238,

title = {Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up},

author = {A. Vogel and A. Cervantes and I. Chau and B. Daniele and J. Llovet and T. Meyer and J. -C. Nault and U. Neumann and J. Ricke and B. Sangro and P. Schirmacher and C. Verslype and C. J. Zech and D. Arnold and E. Martinelli},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85054346991&doi=10.1093%2fannonc%2fmdy308&partnerID=40&md5=6131edba9dd1af598dbfaeda1f957f7f},

doi = {10.1093/annonc/mdy308},

issn = {09237534},

year  = {2018},

date = {2018-01-01},

urldate = {2018-01-01},

journal = {Annals of Oncology},

volume = {29},

pages = {iv238 – iv255},

publisher = {Oxford University Press},

note = {Cited by: 385; All Open Access, Green Open Access, Hybrid Gold Open Access},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Ryder2003iii1,

title = {Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults},

author = {S. D. Ryder},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037407560&doi=10.1136%2fgut.52.suppl_3.iii1&partnerID=40&md5=13ddeddee70fea2fa5688ce86f18bf94},

doi = {10.1136/gut.52.suppl_3.iii1},

issn = {00175749},

year  = {2003},

date = {2003-01-01},

urldate = {2003-01-01},

journal = {Gut},

volume = {52},

number = {SUPPL. 3},

pages = {iii1–iii8},

publisher = {BMJ Publishing Group},

note = {Cited by: 349; All Open Access, Bronze Open Access, Green Open Access},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Llovet1999329,

title = {Prognosis of hepatocellular carcinoma: The BCLC staging classification},

author = {Josep M. Llovet and Concepció Brú and Jordi Bruix},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-0032879468&doi=10.1055%2fs-2007-1007122&partnerID=40&md5=c9acc0b4c0c9d6821e577af7478ccd28},

doi = {10.1055/s-2007-1007122},

issn = {02728087},

year  = {1999},

date = {1999-01-01},

urldate = {1999-01-01},

journal = {Seminars in Liver Disease},

volume = {19},

number = {3},

pages = {329 – 337},

publisher = {Thieme Medical Publishers, Inc.},

abstract = {The classifications of hepatocellular carcinoma (HCC) currently used are based on prognostic factors obtained from studies performed years ago when most tumors were diagnosed at advanced stages and the survival rates were substantially poor. Recent investigations have reviewed the survival of early tumors properly selected to receive radical therapies and the natural outcome of nonsurgical HCC patients. These data enable a new staging system to be proposed, the Barcelona Clinic Liver Cancer (BCLC) staging classification, that comprises four stages that select the best candidates for the best therapies currently available. Early stage (A) includes patients with asymptomatic early tumors suitable for radical therapies -resection, transplantation or percutaneous treatments. Intermediate stage (B) comprises patients with asymptomatic multinodular HCC. Advanced stage (C) includes patients with symptomatic tumors and/or an invasive tumoral pattern (vascular invasion/extrahepatic spread). Stage B and C patients may receive palliative treatments/new agents in the setting of phase II investigations or randomized controlled trials. End-stage disease (D) contain patients with extremely grim prognosis (Okuda stage III or PST 3-4) that should merely receive symptomatic treatment.},

note = {Cited by: 2855},

keywords = {},

pubstate = {published},

tppubtype = {article}

}